Human proapolipoprotein A-II is cleaved following secretion from Hep G2 cells by a thiol protease

Molecular cloning and sequence of the cynomolgus monkey apolipoprotein A-II gene

A clone containing the coding region for cynomolgus monkey (Macaca fascicularis) apolipoprotein A-II has been isolated from a cynomolgus genomic DNA library. The gene spans 1.4 kilobases (kb). The complete nucleic acid sequence of the apolipoprotein A-II gene has been determined, establishing that the gene is interrupted by three intervening sequences of 170, 273 and 394 bp, respectively. The open reading frame encodes a protein of 100 amino acids, and shows 94% sequence similarity with its human equivalent. Both apolipoproteins have identical signal peptide. A noticeable feature is the substitution of mature human Cys-6 for Ser. This change explains the existence of cynomolgus apolipoprotein A-II as a monomer and may have important consequences in the kinetics of this apolipoprotein.

Intracellular modification of human apolipoprotein AII (apoAII) and sites of apoAII mRNA synthesis: comparison of apoAII with apoCII and apoCIII isoproteins

We have studied the intracellular modifications of human apoAII by pulse-chase labeling of HepG2 cell cultures with [35S]methionine or [3H]arginine followed by two-dimensional analysis and autoradiography of the radiolabeled apoAII isoproteins. A short (5.0-min) pulse showed the presence of a precursor form of apoAII (pI = 5.75) designated proapoAII or apoAII3. A 5-10-min chase resulted in a decrease in the relative concentration of the proapoAII coupled with an increase in the relative concentration of a new form (pI = 5.3) designated modified proapoAII or apoAII1. Longer chase resulted in the appearance of the plasma apoAII form and at least five other acidic apoAII isoproteins in the cell lysate and the culture medium. Labeling with [3H]arginine showed that apoAII isoproteins designated 3, 1, -1, and -3 contained the prosegment whereas isoproteins designated 1a, 0, -1a, -2a, -3a, and -4a did not. Comparison of nascent apoAII, apoCII, and apoCIII isoproteins revealed that they were distinctly different on the two-dimensional gels. Neuraminidase treatment converted the acidic apoAII isoproteins to isoproteins 1a and 0 (modified and plasma apoAII forms). The combined data are consistent with the following intra- and/or extracellular modifications of apoAII: (a) modification of the apoAII which results in the net loss of two positive charges; (b) glycosylation of the modified proapoAII with carbohydrate chains containing sialic acid; (c) proteolytic removal of the prosegment and cyclization of the N-terminal glutamine. Analysis of apoAII mRNA distribution in 13 fetal human tissues as well as in cell lines of human origin showed abundance of apoAII mRNA in liver and HepG2 cells and only traces in the intestine.

Secretion of cholesteryl ester transfer protein-lipoprotein complexes by human HepG2 hepatocytes

We have employed immunoaffinity chromatography to characterize the distribution of cholesteryl ester transfer activity in particles secreted by HepG2 hepatocytes. HepG2-secreted cholesteryl ester transfer activity is associated with apoprotein (apo) A-I (58%) as well as apo A-II (55%), and is not associated with apo B or E. In contrast, our previous studies have shown that most (88%) cholesteryl ester transfer activity in human plasma is associated with apo A-I whereas very little (7%) is associated with apo A-II. Thus, the distribution of cholesteryl ester transfer activity in plasma particles likely reflects active remodeling of nascent particles in the plasma compartment. Further data suggested that HepG2 cells secrete a lipid transfer inhibitor activity which is associated with apo E-containing lipoprotein particles. This inhibitory activity is heat labile.

Demonstration that the enzyme that converts precursor of apolipoprotein A-I to apolipoprotein A-I is secreted by the hepatocarcinoma cell line Hep G2

The conversion of the precursor of apolipoprotein A-I (proapoA-I) to apolipoprotein A-I (apoA-I) is known to occur extracellularly by an enzyme that has been shown to be present in plasma. The hepatocarcinoma-derived cell line Hep G2, when grown in culture, secretes proapoA-I. We now show that this cell line also secretes the converting enzyme that correctly processes proapoA-I to mature apoA-I as determined by radio-sequence analyses. The secreted enzyme is inhibited by EDTA and 1,10-phenanthroline, is activated by Ca2+ and is unaffected by both phenylmethylsulfonyl fluoride and diisoprophylfluorophosphate in the same way as the converting enzyme previously described in the plasma. The conversion of proapoA-I to apoA-I effected by this enzyme obeys first-order kinetics and is linear over the first 4 h with a calculated initial velocity of 3.3% conversion per hour. The converting activity is secreted in a time-dependent fashion and parallels the mass of total secreted protein.

Structural requirements of human preproapolipoprotein AI for translocation and processing studied by site-directed mutagenesis in vitro

A full length human serum apolipoprotein AI (apo AI) cDNA clone was isolated from a human liver cDNA library. The EcoRI insertion fragment was cloned into expression vectors pDS5 and pDS12 for in vitro transcription and translation. The primary translation product is correctly translocated and the N-terminal signal sequence of the primary translation product of the wild type apo AI cleaved in the presence of dog pancreatic endoplasmic reticulum (ER) membranes releasing proapo AI. Ala-7 at the C-terminus of the signal sequence and Gln-1 of the prosequence were transposed by site-directed mutagenesis thus mutually exchanging the C-termini Gln-8-Ala-7 of the presequence and Gln-2-Gln-1 of the prosequence. The primary translation product of this mutated preproapo AI cDNA is correctly cotranslationally translocated into the lumen of the ER membranes and remains uncleaved by the signal peptidase. Deletion of the hexapeptide prosequence by site-directed mutagenesis in the preproapo AI cDNA led to a primary translation product which is cotranslationally translocated with processing to the mature apo AI polypeptide. We conclude that neither the proteolytic cleavage of the presequence nor the presence of the prosequence are structurally essential for the cotranslational translocation of apo AI. The amino-acid sequence bordering the cleavage site at the C-terminus of the presequence is without influence for the specificity of the signal peptidase.

Structural and immunological homology of human and porcine pituitary and plasma IRCM-serine protease 1 to plasma kallikrein: marked selectivity for pairs of basic residues suggests a widespread role in pro-hormone and pro-enzyme processing

IRCM-serine protease 1 (SP1), originally isolated from porcine pituitaries and exhibiting preference for cleavage at pairs of basic residues has now been isolated in sufficient quantities to be structurally characterized from both porcine and human pituitaries and plasmas. Whereas the porcine protease shows a high degree of amino acid sequence homology to human plasma pre-kallikrein, the human homologue exhibits an identity of sequence in the first 25 residues of each chain (regulatory and catalytic chains). In addition, human plasma and pituitary IRCM-SP1 and human plasma pre-kallikrein show virtually identical immunological and molecular properties. These data strongly suggest that IRCM-SP1 and plasma pre-kallikrein originate from the same gene product. Purified extracts from perfused rat pituitaries show that 32% of the IRCM-SP1 activity found in normal rat pituitaries, still remain. These data together with the demonstrated association of IRCM-SP1 with particulate fractions of the pituitary suggest that IRCM-SP1 represents a tissue form of plasma pre-kallikrein. The characterization of the digestion products obtained upon reaction of IRCM-SP1 with pro-insulin, ACTH1-39, pro-dynorphin and pro-enkephalin-derived peptides, somatostatin-28, and a pro-renin-like peptide confirmed the high degree of cleavage selectivity of this enzyme for pairs of basic residues.

Synthesis and secretion of plasma cholesteryl ester transfer protein by human hepatocarcinoma cell line, HepG2

We have examined the synthesis, secretion, and functional and physical characteristics of a lipid transfer protein synthesized by a human hepatocellular carcinoma line. We found that this protein shares immunochemical determinants and many other properties with the lipid transfer protein, LTP-I, which has been purified from human plasma. We conclude that the human liver cell line, HepG2, synthesizes and secretes LTP-I. Thus, hepatocytes may be the source of LTP-I in human plasma.

Proapolipoprotein-converting enzymes and high-density lipoprotein early events in biogenesis

The early events in high-density lipoprotein biogenesis involve the extracellular action of two converting enzymes affecting the cleavage of the prosegment of either proapolipoprotein A-I or proapolipoprotein A-II and the generation of mature apolipoprotein (apo) A-I and apo A-II, the main apolipoprotein of high-density lipoproteins. These two converting enzymes differ from each other in mechanism of action and specificity. The observation that they can be secreted by human hepatocarcinoma G2 cells in culture provides an experimental basis for examining the possible coordination between the synthesis and secretion of these two converting enzymes and the events attending the production and cellular export of apo A-I and apo A-II.

Biosynthesis of antifreeze polypeptides in the winter flounder. Characterization and seasonal occurrence of precursor polypeptides

The precursor proteins for winter flounder antifreeze polypeptide (AFP) were isolated from liver using gel filtration chromatography and reverse-phase high-performance liquid chromatography. Two major pro-antifreezes (Mr 5000), corresponding to the precursors for AFP-6 and AFP-8, were characterized by amino acid analyses and automated Edman degradation. These precursors showed significant antifreeze activity. The pro-antifreezes were synthesized in the liver seasonally as demonstrated by immunoblotting and in vitro liver incorporation studies. No mature AFP were detected in liver, thus indicating that the processing of pro-antifreezes, including amidation of the C-termini, occurred mainly in the serum. The function(s) of the prosequences, if any, remain unclear.

Differences in cathepsin B mRNA levels in rat tissues suggest specialized functions

The tissue distribution of mRNAs encoding two lysosomal proteases, cathepsin B and cathepsin D, was examined using cloned cDNAs to probe Northern and dot blots of RNAs extracted from various rat tissues. Cathepsin B mRNA showed a wide range of variation in expression in the tissues analyzed with the highest concentrations found in spleen and kidney, while the cathepsin D mRNA levels were relatively uniform in these same tissues. Significant quantities of cathepsin B mRNA were detected in total RNA from isolated islets of Langerhans but was not detectable in equivalent amounts of RNA from whole pancreas. The wide variations in tissue levels of cathepsin B mRNA suggest that tissue specific controls may regulate its expression and are compatible with the participation of this protease in specialized cellular functions other than intralysosomal protein degradation.

Proteolytic processing and compartmentalization of the primary translation products of mammalian apolipoprotein mRNAs

The steps involved in the initial assembly of apolipoproteins and lipids into supramolecular arrays (nascent lipoprotein particles) are largely unknown. Examination of the proteolytic processing and compartmentalization of the primary translation products of apolipoprotein mRNAs represents one approach to deciphering the molecular details of lipoprotein assembly. The structures of the primary translation products of seven mammalian apolipoprotein mRNAs has been determined in the past several years. The organization of apolipoprotein signal peptides is typical of eukaryotic prepeptides, although an unusual degree of sequence conservation is present among the signal segments of apo AI, AIV, and E. For those apolipoprotein sequences studied in detail, SRP-dependent cotranslational translocation and proteolytic processing appears to be highly efficient and results in sequestration of the processed protein within the lumen of the endoplasmic reticulum (ER). However the mechanism by which these lipid-binding proteins avoid arrest during their translocation through the lipid bilayer of the ER membrane remains obscure. The two principal human HDL apolipoproteins undergo novel extracellular post-translational proteolytic processing, which results in removal of nonhomologous propeptides. The proteases responsible for proapo AI and AII processing appear to be different. The processing of these proapolipoproteins provides a potential series of steps for regulating the ordered assembly of HDL constituents.

Intra- and extracellular modifications of apolipoproteins

This chapter outlined the methods used to study intra- and extracellular modifications of apolipoproteins. These and other related studies have shown that several of the apolipoproteins undergo a series of intra- and extracellular modifications as follows: All apolipoproteins studied contain an 18-26 long signal peptide which is cleaved cotranslationally by the signal peptidase of the rough endoplasmic reticulum. ApoE is further modified intracellularly with carbohydrate chains containing sialic acid and is secreted in the modified form designated apoEs. The modified apoE is subsequently desialated in plasma. ApoA-I is secreted in a proapoA-I form, which consists of 249 amino acids. The N-terminal hexapeptide of proapoA-I is cleaved extracellularly by a proapoA-I to plasma apoA-I converting protease. This cleavage generates the plasma apoA-I form which consists of 243 amino acids. Other known apolipoprotein modifications include the modification of apoB, apoC-III, and apoD with carbohydrate chains that contain sialic acid and the proteolytic cleavage of the proapoA-II segment. At the present time we are able to distinguish several isoprotein forms for a particular apolipoprotein. In addition, we began to understand the biochemical changes which lead to a few of these isoproteins. Future research should be directed toward a better understanding not only of the structure but most importantly of the physiological significance of the different apolipoprotein forms.